Brian Mueller - May 30, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
May 30, 2024
Transactions value $
-$39,856
Form type
4
Date filed
5/31/2024, 06:28 PM
Previous filing
Mar 19, 2024
Next filing
Jul 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $20.6K +300 +0.42% $68.65 72.2K Apr 30, 2024 Direct F1
transaction BMRN Common Stock Options Exercise $316K +5K +6.93% $63.10 77.2K May 30, 2024 Direct F2
transaction BMRN Common Stock Sale -$376K -5K -6.48% $75.19 72.2K May 30, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -5K -100% $0.00* 0 May 30, 2024 Common Stock 5K $63.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on August 18, 2023.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.